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Sincethedysregulationofribosomebiogenesisiscloselyassociatedwithtumorprogression,inthecurrentstudy,thecriticalroleof
ribosome biogenesis related signaling was investigated in melatonin and/or puromycin induced apoptosis in MDA-MB-231 breast
cancer cells. Despiteitsweak cytotoxicity, melatonin from3mMattenuated theexpressionof45S pre-ribosomalRNA(pre-rRNA),
UBF as a nucleolar transcription factor, and fibrillarin at mRNA level and consistently downregulated nucleolar proteins such as
UBF and fibrillarin at protein level in MDA-MB-231 cells. Furthermore, immunofluorescence assay revealed that UBF was also
degraded by melatonin in MDA-MB-231 cells. In contrast, melatonin attenuated the expression of survival genes such as Bcl-xL,
M cl-1,cyclinD1,andcyclinE,suppressedthephosphoryla tionofAKT ,m TOR,andST A T3,andclea vedP ARPandactiva tedcaspase
3onlyatahighconcentration of12mM.However,combinedtreatmentofmelatonin(3mM)andpuromycin(1𝜇M)synergistically
inhibited viability, attenuated the expression of 45S pre-rRNA and UBF, and consistently downregulated UBF, XPO1 and IPO7,
procaspase 3, and Bcl-xL in MDA-MB 231 cells. Overall, these findings suggest that melatonin can be a cancer preventive agent by
combination with puromycin via the inhibition of 45S pre-rRNA and UBF in MDA-MB 231 breast cancer cells.
1. Introduction
B r eas tca ncer sa r eo neo fthema jo rcas ual tieso fdea tha mo n g
women aged 30–55 years. Though several drugs such as
tamoxifen, doxorubicin, and raloxifene have been clinically
used to reduce the risk of breast cancer, side effects and
resistance to chemotherapy are still hot issues [1]. Thus,
the combined therapy of commercial anticancer agents with
natural compounds is considered as an attractive strategy
to reduce side effects or resistance, since it can meet the
antitumor efficacy with lower doses of anticancer agents.
Melatonin,ahormonewhichisgeneratedandsecretedby
t h ep i n e a lg l a n dd u r i n gt h en i g h t ,i sk n o w nt oh a v ev a r i o u s
physiological functions by regulating sleep [2], depression
[3],orage[4]andantioxidantactivity[5].Thereby,melatonin
was reported to ameliorate several diseases such Alzheimer’s
disease [4], obesity [6], cardiovascular [7], bone disease [8],
and cancer [9, 10] by combination or single treatment. Espe-
cially, melatonin in breast cancer was known to suppress the
estrogen signaling pathway and vascular endothelial growth
factor (VEGF) [11] as well as inhibit aromatase expression
and activity [12] in MCF-7 cells. Nevertheless, there is
no evidence that ribosome biogenesis related signaling is
involvedinmelatonininducedapoptosisinbreastcancercells
until now.
Ribosome biogenesis in the nucleolus is involved in
cell growth and proliferation [13] via protein synthesis [14]
and also involves the production of four rRNAs and2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Cytotoxicity of melatonin and puromycin in MDA-MB-231 breast cancer cells. Various concentrations of melatonin (0, 1, 2, 4, 8, or
16mM) (a) or puromycin (0, 0.5, 1, 2, 4, or 8 𝜇M/mL) (b) were treated in MDA-MB-231 cells for 24h, and then cell viability was determined
by MTT assay. The data were expressed as means ± SD.
∗𝑃 < 0.05,
∗∗𝑃 < 0.01,
∗∗∗𝑃 < 0.001 versus untreated control.
approximately 80 ribosomal proteins. 45S pre-rRNA (pre-
ribosomalRNAtranscript)istranscribedbypolymerase(Pol)
I to generate mature 18S, 5.8S, and 28S rRNAs. Pol I is
highly regulated in cancer [15] and overexpression of pre-
rRNA synthesis is correlated with the rate of cancer cell
proliferation [16, 17]. Thus, inhibition of rRNA synthesis
makescellsundergocellcyclearrest,apoptosis,orsenescence
[18]. Also, there is accumulating evidence that nucleolar
proteins including upstream binding factor (UBF) recognize
the promoter of ribosomal RNA genes and mediate the
ribosomal RNA synthesis [19].
Thus,inthecurrentstudy,theroleofribosomebiogenesis
was focused on apoptosis induced by melatonin and/or
puromycin in MDA-MD-231 breast cancer cells.
2. Material and Methods
2.1. Chemicals and Reagents. Melatonin (N-acetyl-5-metho-
xytryptamine; molecular weight: 232.28) and puromycin
(C22H29N7O5,m o l e c u l a rw e i g h t :4 7 1 . 5 1 )w e r ep u r c h a s e d
from Sigma-Aldrich (Sigma, St. Louis, MO). Melatonin and
puromycin were prepared in DMSO (Sigma, St. Louis, MO)
a n ds t o r e da ss m a l la l i q u o t sa t−70
∘Cf o ru s e .
2.2. Cell Culture. Human breast cancer cell lines MDA-
MB-231 (ATCC HTB-26) were obtained from American
Type Culture Collection (ATCC) and cultured in RPMI1640
medium (Welgene, Daegu, South Korea) supplemented with
10% fetal bovine serum (FBS), 2𝜇ML - g l u t a m i n ea n dp e n i -
cillin/streptomycin (Gibco, Carlsbad, CA, USA) at 5% CO2
conditions.
2.3. Cytotoxicity Assay. To evaluate the cytotoxicity of mela-
tonin and/or puromycin, MTT assay (Sigma, St. Louis, MO)
was used. MDA-MB-231 cells were seeded onto 96-well
microplates at a density of 2 × 10
4 cells/well and treated
with various concentrations of melatonin (1, 2, 4, 8, and
16mM) and/or puromycin (0, 0.25, 0.5, 1, 2, 4𝜇M) for 24h.
MTT solution (1mg/mL) for 2h was incubated and MTT
lysis buffer (20% SDS and 50% dimethylformamide) was
incubated overnight. Optical density (OD) was measured
usingamicroplatereader(MolecularDevicesCo.,Sunnyvale,
CA) at 570nm. To calculate the viability of MDA-MB-231
cells,thepercentageofviablecellsinmelatonin-treatedgroup
versus untreated control was used as the following equation.
Cellviability(%)=[OD(drug)−OD(Blank)]/[OD(Control)
− OD (Blank)] ×100.
2.4. Western Blotting. MDA-MB-231 breast cancer cells were
lysed in Radioimmunoprecipitation Assay (RIPA) buffer
(50mM Tris-HCl, pH 7.4, 150mM NaCl, 1% NP-40, 0.25%
sodium deoxycholic acid, 1M EDTA, 1mM Na3VO4,1m M
NaF and protease inhibitors cocktail). To quantify pro-
tein samples, Bio-Rad DC protein assay kit II (Bio-Rad,
Hercules, CA) was used. Proteins were separated by elec-
trophoresis on SDS-PAGE gel and electrotransferred onto
a Hybond enhanced chemiluminescence (ECL) transfer
membrane (Amersham Pharmacia, Piscataway, NJ). After
blocking with 5% Bovine Serum Albumin (BSA), the mem-
brane was probed with antibodies for fibrillarin, PARP, Bcl-
xL,M c l - 1L, phospho-STAT3, phospho-mTOR (Cell signal-
ing Technology, Danvers, MA), UBF, exportin 1 (XPO1),
Importin (IPO7), caspase-3, cyclin D1, cyclin E, phospho-
A K T( S a n t aC r u zB i o t e c h n o l o g i e s ,S a n t aC r u z ,C A ) ,a n d𝗽-
actin (Sigma Aldrich Co., St. Louis, MO) followed by expos-
ing to horseradish peroxidase (HRP) conjugated secondary
anti-mouse or rabbit antibodies (AbD Serotec, Kidlington,
UK). To detect protein expression, ECL system (Amersham
Pharmacia, Piscataway, NJ) was used.
2.5. Real-Time Quantitative RT-PCR (RT-qPCR). Total
RNA was isolated from MDA-MB-231 cells with QIAzolEvidence-Based Complementary and Alternative Medicine 3
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Figure2:Effectofmelatoninontheexpressionof45Spre-rRNAandnucleolar proteinsinMDA-MD-231cells.(a)Effectofmelatoninon45S
pre-rRN A.MD A -MB-231cellsweretrea tedwithvariousconcen tra tionsofmela tonin(0,3,6,12mM)for24h.RN Awasisola tedandanalysed
for the expression of 45S pre-rRNA by RT-qPCR. (b) Effect of melatonin on nucleolar proteins by western blotting. Western blotting analysis
was performed to detect UBF, fibrillarin, XPO1, IPO7, and 𝗽-actin. (c) Effect of melatonin on nucleolar proteins by RT-qPCR. RNA was
i so la t eda n da n al y sedf o rth em R N Ae x p r e s s i o no fU B F ,fi b rilla ri n ,a n dN C Lb yR T - q P C R.G A P D Ha si n t e rn alc o n tr o lw a su sedt on o rm al i z e
the expression of data. Data were presented as means ± S.D. 𝑁=3 ,
∗P < 0.05 versus untreated control.
(Invitrogen). A reverse transcription kit (Promega,WI,USA)
w a su s e dt oc o n s t r u c tt h et e m p l a t ec D N A .R T - q P C Rw a s
performed with the LightCycler TM instrument (Roche
Applied Sciences, Indianapolis, IN) according to the
manufacturer’s protocol. The mRNA level of GAPDH was
used to normalize the expression of genes of interest. The
primers used were as follows: UBF forward: 5
򸀠-AAC ACC
CAG ACT TCC CAA AG-3
򸀠,r e v e r s e :5
򸀠-TCT CCG GAA
G C TC C TT G TA T - 3
򸀠; Fibrillarin forward: 5
򸀠-GGT GGA
TGT GAT CTT TGC TG-3
򸀠,r e v e r s e :5
򸀠-TGG CCT TAA
TGG AAA TCA CA-3
򸀠;N C Lf o r w a r d :5
򸀠-AGC AAA GAA
GGT GGT CGT TT-3
򸀠,R e v e r s e :5
򸀠-CTT GCC AGG TGT
GGT AAC TG-3
򸀠; 45S pre-rRNA forward: 5
򸀠-CTC CGT
TAT GGT AGC GCT GC-3
򸀠,r e v e r s e :5
򸀠-GCG GAA CCC
TCG CTT CTC-3
򸀠; GAPDH forward: 5
򸀠-CCA CTC CTC
CAC CTT TGA C-3
򸀠,r e v e r s e :5
򸀠-ACC CTG TTG CTG TAG
CCA-3
򸀠.
2.6. Immunocytochemistry Analysis. MDA-MB-231 cells in
t h ep r e s e n c eo ra b s e n c eo fm e l a t o n i nw e r efi x e di n4 %
paraformaldehyde, permeabilized in 0.3% Triton X-100, and
blocked for 30min in 1% BSA/10% fetal bovine serum at
room temperature. Fixed cells were incubated with primary
antibody (𝗼-UBF) at 4
∘Co v e r n i g h t .A ft e rw a s h e dw i t hP B S
containing0.1%BSA,thecellswereincubatedwithAlexFluor
568goatrabbit-IgGantibody(Invitrogen)(1:500dilution)at
room temperature for 30min. After washing twice, the cells
were stained with 5mg/mL 4,6-diamidino-2-phenylindole
(DAPI; Sigma). Images were obtained by a Delta Vision
imaging system (Applied Precision, Issaquah, WA, USA).4 Evidence-Based Complementary and Alternative Medicine
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Figure3:EffectofmelatoninonthesurvivalgenesandapoptoticproteinsinMDA-MB-231cells.(a)Effectofmelatoninonsurvivalgenes(b)
Effect of melatonin on procaspase 3 and PARP. Cells were treated with melatonin (3mM) for 24h. Western blotting analysis was performed
with antibodies of above survival, apoptotic genes, and 𝗽-actin.
2.7. Statistical Analysis. Statistical analysis of the data was
conducted using Sigmaplot version 12 software (Systat Soft-
ware Inc., San Jose, CA) or Prism (GraphPad Software, Inc.,
CA,USA).Alldatawerepresentedasmeans±standarddevi-
ation (SD). The statistically significant differences between
control and melatonin and/or puromycin treated cells were
performed by the Student’s 𝑡 test.
3. Results
To target the synergistic antitumor activity by melatonin
and puromycin, we evaluated the cytotoxicity of melatonin
and/or puromycin in MDA-MB-231 cells by MTT assay. As
shown in Figure 1, melatonin showed weak cytotoxicity only
at the pharmacologically high concentrations of 8 and 16mM
in MDA-MB-231 cells, while puromycin exerted significant
cytotoxicity in a dose dependent manner (0.5∼4𝜇g ≤ 1∼
8𝜇M). To evaluate the potential of melatonin to regulate the
ribosome synthesis, 45S pre-rRNA synthesis by RNA pol I in
melatonintreatedMDA-MB-231cellswasdeterminedbyRT-
qPCR assay. As shown in Figure 2(a), though the inhibition
wasini tia tedfr o m3mMinMD A -MB-23 1cells,thesta tistical
significance (𝑃 < 0.05) was recognized only at 12mM of
melatonin.
Next,weassessedtheeffectofmelatoninonthenucleolar
proteins such as UBF, fibrillarin, or XPO1 and IPO7 which
a r ei n v o l v e di nr i b o s o m eb i o g e n e s i s .O u rw e s t e r nb l o t t i n g
revealed that melatonin suppressed the expression of UBF
and fibrillarin in a dose dependent manner but not IPO7
and XPO1 (Figure 2(b)). Consistently, UBF and fibrillarin at
mRNA level were also downregulated in melatonin treated
MDA-MB-231 cells, but not nucleolin (NCL) which is one of
nucleolar proteins (Figure 2(c)).
We evaluated the effect of melatonin on the mTOR/
AKT/STAT3 signals which are involved in cell growth. As
shown in Figure 3, western blotting showed that melatonin
down-regulated the phosphorylation of AKT, mTOR, and
STAT3, attenuated the expression of survival genes such as
McL-1, Bcl-xL, cyclin D1, and cyclin E, and activated caspase
and cleaved PARP only at high concentration of 12mM
treated MDA-MB-231 cells.
To check the effects of melatonin on intracellular local-
ization of UBF, immunocytochemistry was performed. As
shown in Figure 4, melatonin dispersed UBF aggregates at 3
or6mMfromnucleolitothenucleoplasmandproteolytically
induced degradation at 12mM in MDA-MB-231, while UBF
wasaggregatedinthenucleoliinuntreatedcontrol(Figure 4).
To examine the synergistic effect of melatonin on
puromycin mediated cell death, melatonin (3mM) was
cotreated with puromycin (1𝜇M) in MDA-MB-231 for 24h.
Though combined treatment of melatonin and puromycin
did not show any significant cytotoxicity against MDA-
MB-231 cells (Figure 5(a)) compared to puromycin alone,
cotreatment of melatonin and puromycin significantly sup-
pressed 45S pre-rRNA in MDA-MB-231 cells compared to
puromycin(Figure 5(b)).Next,toconfirmwhetherribosome
biogenesisrelatedgenesmediatecytotoxicityofco-treatment
of melatonin and puromycin in MDA-MD-231 cells, western
blotting was carried out. As shown in Figure 6(a),U B F ,
XPO1, and IPO7 were suppressed by combined treatment
of melatonin and puromycin, but not fibrillarin. Further-
more, RT-qPCR revealed that UBF expression at mRNA
level was significantly downregulated by co-treatment of
melatonin and puromycin in MDA-M231 cells (Figure 6(b)).
In addition, the expression of procaspase 3 and BcL-xL was
attenuated by cotreatment of melatonin and puromycin in
MDA-MB-231 cells (Figure 6(c)).Evidence-Based Complementary and Alternative Medicine 5
UBF
C
o
n
t
r
o
l
(a)
UBF + DAPI
(b)
M
e
l
a
t
o
n
i
n
 
(
3
m
M
)
(c) (d)
M
e
l
a
t
o
n
i
n
 
(
6
m
M
)
(e) (f)
M
e
l
a
t
o
n
i
n
 
(
1
2
m
M
)
(g) (h)
Figure4:DistributionofUBFlocalizationinmelatonintreatedMDA-MB-231cells.LocalizationofUBFinMDA-MB-231cellsintheabsence
or presence of melatonin (3, 6, 12mM) were fixed and immunostained with 𝗼-UBF. The localization of UBF was analyzed by a Delta Vision
imaging system (Applied Precision). Nuclei were stained with DAPI. Scale bar, 20𝜇m.
4. Discussion
Ribosome biogenesis is a very complex process involving
transcriptional and posttranscriptional steps in the nucleoli,
where ribosomal RNA (rRNA) is synthesized into ribosomal
subunits mainly through the RNA polymerase I (Pol I)
transcription machinery [20]. Previous papers suggest that
blocking or inhibiting rRNA synthesis can be a promising
target for cancer treatment [21, 22]. Melatonin was reported
to inhibit the growth of estrogen receptors (ER) positive6 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Combined effect of melatonin and puromycin on the viability and 45S pre-rRNA in MDA-MB-231 cells. (a) Effect of melatonin
and/or puromycin on the viability of MDA-MB-231 cells. MDA-MB-231 cells were seeded at a density of 2×1 0
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breast cancer such as MCF-7, T47D and ZR-75-1 cells more
effectively than estrogen negative breast cancer cells such
as BT-20, MDA-MB-231, MDA-MB-364, Hs587t, T47Dco
[23, 24]. Specifically, aggressive breast cancer cells displayed
increased synthesis of 45S pre-rRNA with activation of an
alternative pre-rRNA synthetic pathway [25]. UBF is an
RNA polymerase I-specific transcription [26]a n dfi b r i l l a r i n
is involved in pre-rRNA processing, pre-rRNA methylation,
and ribosome assembly [27]. In the current study, though
melatonin showed weak cytotoxicity in MDA-MB-231 breast
cancer cells, it effectively attenuated the expression of 45S
pre-rRNA, UBF, and fibrillarin at mRNA level as well as
downregulated nucleolar proteins such as UBF and fibril-
l a r i na tp r o t e i nl e v e li nM D A - M B - 2 3 1c e l l s .C o n s i s t e n t l y ,
immunofluorescence assay showed that UBF was dispersed
or proteolytically degraded by melatonin, implying mela-
t o n i ne ff e c t i v e l yd i s r u p t sr i b o s o m eb i o g e n e s i sv i ai n h i b i t i o n
of RNA polymerase I transcription.
There is accumulating evidence that survival genes are
involved in ribosome biogenesis. Among them, mTOR coor-
dinates transcription by all three classes of nuclear RNA
polymerases [28, 29] and cyclin E upregulation promotes the
g r o w t ha n dc e l lc y c l ep r o g r e s s i o nb yr i b o s o m a lp r o t e i nL 6
[30]. There are accumulating evidences that mTOR signal
controls several steps in ribosome biogenesis such as the
rRNA gene transcription and pre-rRNA processing [29].
Here, melatonin attenuated the expression of survival genes
such as Bcl-xL, Mcl-1, cyclinD1, and cyclin E, suppressed the
phosphorylation of STAT3, mTOR, and AKT and induced
t h ec l e a v a g eo fP A R Pa n da c t i v a t e dc a s p a s e3i n d i c a t i n gt h a t
melatonin can induce apoptosis and inhibit the proliferation
via inhibition of anti-apoptotic genes such as BCL-xL, Mcl-1,
cyclin D1, cyclin E, p-STAT3, p-mTOR, and p-AKT at high
concentration in estrogen negative MDA-MB-231 cells.
Belin et al. suggested that dysregulation of ribosome
biogenesis has been linked with tumor progression by
increasing ribosome synthesis in human breast cancer cells
[25].Ribosomesynthesisinhumanbreastcancerprogression
was increased up to 20% [25]. The relatively high level of
ribosomalRNA(rRNA)wasobservedinrapidlyproliferating
tumor tissue [31] and rRNA synthesis also was linked to cel-
lular proliferation rate. Thus, when rRNA synthesis becomes
slow, cells undergo apoptosis, autophagy, or senescence [18].
Ribosomal RNA synthesis is a key molecular process for cell
proliferation. In this process, UBF is involved in regulating
rDNA transcription at the nucleolus, together with RNA
polymeraseIandrecruitingtheSL-1andPolI[32].Fibrillarin
mediates the processing of rRNA [33]. IPO7 and XPO1 for
nuclear import and export signals regulate ribosomal stress
[34]. In the present study, combined treatment of melatonin
(3mM) and puromycin (1𝜇M) synergistically attenuated
the expression of 45S pre-rRNA and UBF, suppressed cell
viability, and also consistently abrogated the expression of
UBF, XPO1, and IPO7, procaspase 3, and Bcl-xL in MDA-
MB 231 cells, indicating the synergistic, antiproliferative and
apoptotic effects between melatonin and puromycin even
in estrogen negative MDA-MB-231 cells via inhibition of
rRNA synthesis and Pol I transcription. These data were sup-
portedbyprevioussimilarevidencethatmelatoninpromoted
puromycin-induced apoptosis in human leukemia HL-60
cells [10].
In summary, melatonin inhibited 45S pre-rRNA in a
dose dependent manner and attenuated the level of UBF
a ndm T O R.S imila rl y ,thep r o-a po p t o ticsignalsw er ealsou p-
regulated in melatonin treated MDA-MB-231 cells. Further-
more, co-treatment with melatonin and puromycin induced
the apoptosis via downregulation of 45S pre-rRNA and UBF.
Overall, these findings indicate that the inhibition of 45S
p r e - r R N Aa n dU B Fb ym e l a t o n i ni sc r i t i c a l l yi n v o l v e di n
the synergistic antitumor effect by combined treatment of
melatonin and puromycin in aggressive MDA-MB 231 breast
cancer cells and suggest melatonin has cancer chemothera-
peutic potential in breast cancer cells.
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